Roche and Causaly Webinar: AI for smarter portfolio management - Moving beyond serendipity in early R&D

Peggy Westlotorn
published on April 12, 2022

Pharmaceutical research is inherently risky and failed or discontinued projects are an inevitable part of the R&D process. A key challenge is that competitive information and the biological validation necessary to decide on target selection and clinical development is often unavailable in a timely or holistic manner. With the volume of information increasing exponentially – from biomedical literature, to labels, to clinical trials, to conference readouts, to news – tackling this problem is a massive challenge.

In this on-demand webinar Ivan John Clement, previous R&D Portfolio Data Strategy Lead from Roche and Yiannis Kiachopoulos, CEO of Causaly discuss how:

  • Roche is partnering with Causaly to build a unified and systematic approach to drive better project and portfolio level decisions.
  • A user-centric application of AI for smarter portfolio management leads to value creation in early R&D.
  • Causaly’s machine-reading algorithms truly understand text like a human does, allowing Roche and other users to receive simple answers to complex questions within seconds.

Request access to the recording here

Why poor target validation is costing pharmaceutical businesses millions

It has been well documented that only 1 out of 10 compounds that enter clinical trials makes it to market¹. That is an astonishing 90%...

  • Point of View

Watch Causaly’s panel discussion from Discovery Europe

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe...

  • General

Webinar - Knowledge discovery reimagined: finding new hypotheses with Causaly Cloud

It is well recognized among scientists that target selection can improve clinical trial success rates (1). Being able to stay up to date...

  • use case

Sign up for Causaly newsletter